Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03256136 · ClinicalTrials.gov registry record · Phase 2
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03256136: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03256136 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03256136, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: * Nivolumab * Carboplatin * Pemetrexed * Ipilimumab
Interventions
- DRUG Carboplatin
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2019-08-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03256136
The ClinicalTrials.gov registry entry for NCT03256136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT03256136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03256136 about?
NCT03256136 is a clinical study titled "Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC". This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: * Nivolumab * Carboplatin * Pemetrexed * Ipilimumab
What is the current status of trial NCT03256136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-11-22. Estimated completion is 2019-08-19.
What interventions are being tested in trial NCT03256136?
The interventions under investigation include: Carboplatin (DRUG), Nivolumab (DRUG), Ipilimumab (DRUG), pemetrexed (DRUG).
Who is sponsoring clinical trial NCT03256136?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.